External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort

Background: External validation of risk calculators (RCs) is necessary to determine their clinical applicability beyond the setting in which these were developed. Objective: To assess the performance of the Rotterdam Prostate Cancer RC (RPCRC) and the Prostate Biopsy Collaborative Group RC (PBCG-RC)...

Full description

Bibliographic Details
Main Authors:	Jan Chandra Engel, Thorgerdur Palsdottir, Donna Ankerst, Sebastiaan Remmers, Ashkan Mortezavi, Venkatesh Chellappa, Lars Egevad, Henrik Grönberg, Martin Eklund, Tobias Nordström
Format:	Article
Language:	English
Published:	Elsevier 2022-07-01
Series:	European Urology Open Science
Subjects:	Prostate cancer Risk calculators External validation study Recalibration of risk prediction tools Prostate cancer screening
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168322005857

Similar Items

The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics—Real-world Evidence from 2018 to 2022
by: Thorgerdur Palsdottir, et al.
Published: (2024-03-01)

Cost Analysis of Prostate Cancer Care Using a Biomarker-enhanced Diagnostic Strategy with Stockholm3
by: Olga Dianna McLeod, et al.
Published: (2024-08-01)

Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
by: Joel Andersson, et al.
Published: (2022-10-01)

A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
by: Mauritz Waldén, et al.
Published: (2022-04-01)

Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data
by: Sebastiaan Remmers, et al.
Published: (2022-02-01)

Prostate cancer - risk factors and prevention strategies
by: Jakub Rybak, et al.
Published: (2023-10-01)

Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis
by: Brecht Chys, et al.
Published: (2020-03-01)

Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center
by: Philipp Krausewitz, et al.
Published: (2024-03-01)

Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?
by: Ugo Giovanni Falagario, et al.
Published: (2021-01-01)

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
by: Juan Morote, et al.
Published: (2023-07-01)

Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials
by: Jonathan A. Gelfond, et al.
Published: (2022-03-01)

Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification
by: Petter Davik, et al.
Published: (2022-09-01)

Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy
by: Sebastiaan Remmers, et al.
Published: (2022-02-01)

Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
by: Fredrik Jäderling, et al.
Published: (2024-08-01)

Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detection
by: Igor Sorokin, et al.
Published: (2015-01-01)

Can microfocal prostate cancer be regarded as low-risk prostate cancer?
by: Seung Hwan Lee, et al.
Published: (2013-12-01)

The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study
by: Yi-Shuo Wu, et al.
Published: (2016-01-01)

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
by: Subhabrata Mukherjee, et al.
Published: (2021-02-01)

Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer
by: Vinayak Muralidhar, et al.
Published: (2016-02-01)

The role of endogenous testosterone in relationship with low- and intermediate-risk prostate cancer: a systematic review
by: Antonio Benito Porcaro, et al.
Published: (2024-10-01)

Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy
by: Tobias Nordström, et al.
Published: (2017-10-01)

Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?
by: Joseph Safdieh, et al.
Published: (2016-08-01)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
by: Brian D. Kelly, et al.
Published: (2023-07-01)

The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam
by: Sebastiaan Remmers, et al.
Published: (2023-05-01)

The association between sexual function and prostate cancer risk in US veterans
by: Daniel F Zapata, et al.
Published: (2017-01-01)

Impact of Benign Prostatic Hyperplasia and/or Prostatitis on the Risk of Prostate Cancer in Korean Patients
by: Sung Han Kim, et al.
Published: (2021-04-01)

Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer
by: Sha Zhu, et al.
Published: (2020-01-01)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
by: Sneha Parekh, et al.
Published: (2022-07-01)

Hematospermia does not increase the risk of prostate cancer detection in prostate biopsy
by: Jae Ryun Park, et al.
Published: (2024-09-01)

Risk Calculator Strategy Before Magnetic Resonance Imaging Stratification for Biopsy-naïve Men with Suspicion for Prostate Cancer: A Cost-effectiveness Analysis
by: Konstantius R.V. Straat, et al.
Published: (2024-12-01)

Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer
by: Chaoran Ma, et al.
Published: (2023-04-01)

Navigating the evolving diagnostic and therapeutic landscape of low- and intermediate-risk prostate cancer
by: Fabio Zattoni, et al.
Published: (2024-10-01)

Prostate‐derived circulating microRNAs add prognostic value to prostate cancer risk calculators
by: Morgan L. Zenner, et al.
Published: (2023-11-01)

Effect of Glison index on survival of patients with localized prostate cancer in Samara region
by: R. D. Andreeva, et al.
Published: (2022-05-01)

BioPrev-C – development and validation of a contemporary prostate cancer risk calculator
by: Thomas Hermanns, et al.
Published: (2024-02-01)

Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population
by: Yi-Shuo Wu, et al.
Published: (2019-01-01)

The mendelian randomized study revealed the association of prostatitis with prostate cancer risk
by: Jun Chen, et al.
Published: (2024-10-01)

Active surveillance of patients with low and intermediate risk prostate cancer
by: Ramilya D. Andreeva, et al.
Published: (2023-09-01)

Poultry consumption and prostate cancer risk: a meta-analysis
by: Qian He, et al.
Published: (2016-02-01)

The economic burden of prostate cancer – a Swedish prevalence-based register study
by: Shuang Hao, et al.
Published: (2020-05-01)